



May 29, 2026

BSE Limited Floor 25, P. J. Towers Dalal Street, Mumbai - 400 001 Scrip Code: 530019	The National Stock Exchange of India Limited Exchange Plaza Bandra Kurla Complex, Bandra (E) Mumbai - 400 051 Symbol: JUBLPHARMA
---	---

Subject: USFDA Inspection Update - Contract manufacturing facility at Montreal, Canada

Dear Sirs,

In continuation to our previous letters dated February 13, 2026 and November 4, 2025, we are enclosing herewith an update with respect to USFDA Inspection at Contract manufacturing facility at Montreal, Canada communication in accordance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Date and Time of receipt - May 28, 2026, 08:49 AM (PST) i.e. May 28, 2026, 9:19 PM (IST).

We request you to take the same on record.

Thanking you,
Yours faithfully,

For **Jubilant Pharmova Limited**

Naresh Kapoor
Company Secretary

Encl: As above

A Jubilant Bhartia Company

OUR VALUES



Jubilant Pharmova Limited
1-A, Sector 16-A,
Noida-201 301, UP, India
Tel: +91 120 4361000
Fax: +91 120 4234895-96
www.jubilantpharmova.com

Regd Office:
Bhartiagram, Gajraula
Dist. Amroha - 244 223
UP, India
CIN : L24116UP1978PLC004624



Jubilant Pharmova Limited

1A, Sector 16A, Noida – 201301, India

Tel.: +91 120 4361000

www.jubilantpharmova.com

USFDA Inspection Update - Contract manufacturing facility at Montreal, Canada

Noida, May 29, 2026: Jubilant Pharmova Limited (“Company”) today announced that Jubilant HollisterStier General Partnership (“JHSGP”) has received a communication from the United States Food and Drug Administration (USFDA) conveying the completion of its review of the Establishment Inspection Report for the inspection conducted at JHSGP’s Kirkland, Canada facility (16751 Trans-Canada Highway) during October 20 to November 3, 2025. The review has resulted in the issuance of a Warning Letter.

JHSGP has been proactively engaging with the USFDA and has already initiated appropriate corrective and preventive actions. The Company is committed to addressing the observations comprehensively.

The Company would like to emphasize current operations at JHSGP are proceeding under enhanced controls and oversight while remediation efforts are actively underway.

JHSGP is jointly owned by subsidiaries of Jubilant Pharma Limited, a wholly owned subsidiary of the Company.

About Jubilant HollisterStier General Partnership (Canada)

Jubilant HollisterStier General Partnership is a Canada based strategic alliance, jointly owned by subsidiaries of Jubilant Pharmova Limited, Jubilant HollisterStier Inc., Draxis Pharma LLC and 1359773 B.C. Unlimited Liability Company. This partnership is key contributor to the company’s global CDMO capabilities, offering contract manufacturing services for sterile products, including liquid and lyophilized injectables, ophthalmic solutions and sterile ointments.

About Jubilant Pharma Limited

Jubilant Pharma Limited (JPL), a Company incorporated under the laws of Singapore and a wholly-owned subsidiary of Jubilant Pharmova Limited, is an integrated global pharmaceutical company engaged in manufacturing and supply of Radiopharmaceuticals with a network of 45 radio-pharmacies in the US, Allergy Immunotherapy, Contract Manufacturing of Sterile Injectables and Non-sterile products and Solid Dosage Formulations through multiple manufacturing facilities that cater to all the regulated market including USA, Europe and other geographies. The Company has a team of around 3,200 multicultural people across the globe and is committed to delivering value to its customers spread across over 75 countries. It is well recognized as a 'Partner of Choice' by leading pharmaceutical companies globally.

About Jubilant Pharmova Limited

Jubilant Pharmova Limited is an integrated global pharmaceutical company engaged in Radiopharma, Allergy Immunotherapy, Contract Development and Manufacturing of sterile injectable, Contract Research Development and Manufacturing, Generics and Proprietary Novel Drugs businesses. With a network of 45 radiopharmacies in the USA, the Radiopharma business is engaged in manufacturing and supply of



radiopharmaceutical products and services. The Allergy Immunotherapy business is involved in the manufacturing and supply of allergic extracts and venom products in the USA and other markets such as Canada, Europe and Australia. Contract Development and Manufacturing of sterile injectables, with facilities in Spokane, USA, and Montreal, Canada, delivers end-to-end manufacturing solutions, including sterile fill-and-finish injectables (liquid and lyophilized), comprehensive ophthalmic products (liquids, ointments and creams) and ampoules. Contract Research Development and Manufacturing business provides end-to-end drug discovery and development services to the pharmaceutical and biotech industries through three world class research centres (two in India and one in France) and a US FDA approved, Active Pharmaceutical Ingredients manufacturing facility in Nanjangud, Karnataka. The Generics business focuses on development, manufacturing and distribution of Solid Dosage Formulations through multiple manufacturing facilities that cater to all the regulated market including USA, Europe and other geographies. Proprietary Novel Drugs is an innovative biopharmaceutical business developing breakthrough therapies in the area of oncology and auto-immune disorders. Jubilant Pharmova has a team of around 5,500 multicultural people across the globe. The Company is well recognised as a 'Partner of Choice' by leading pharmaceuticals companies globally. For more information, please visit: www.jubilantpharmova.com.

For more information, please contact:

For Investors

Pankaj Dhawan

Phone: +91 120 436 1105

E-mail: Pankaj.dhawan@jubl.com

Siddharth Rangnekar

CDR India

Phone: +91 97699 19966

E-mail: siddharth@cdr-india.com

For Media

Sandipan Ghatak

Phone: +91-98107 76182

E-mail: sandipan.ghatak@jubl.com

Jyoti Sharma

Ad Factors PR

Phone: +91 9810519900

E-mail: jyoti.sharma@adfactorspr.com

Disclaimer

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Pharmova may, from time to time, make additional written and oral forward looking statements, including statements contained in the company's filings with the regulatory bodies and its reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.